Table 4.
Drug | Evidence for beneficial impact on PsA (+ or −) | ||||
---|---|---|---|---|---|
Signs/symptoms | Radiographic damage/progression | Enthesitis | Dactylitis | Axial involvement | |
Methotrexate [105–108] | − | Inconclusive | Unknown | Unknown | − |
Sulfasalazine [109–111] | + | − | − | − | − |
Leflunomide [112–114] | + | Unknown | Unknown | Unknown | − |
Cyclosporine A [115–117] | + | Unknown | Unknown | Unknown | − |
Biologics | |||||
Anti-TNF-α antibodies [2] | + | + | + | + | Unknowna |
Etanercept [125, 126] | + | + | + | + | Unknowna |
Infliximab [118, 119] | + | + | + | + | Unknowna |
Adalimumab [120, 121] | + | + | Inconclusive | Inconclusive | Unknowna |
Golimumab [122, 123] | + | + | + | + | Unknowna |
Certolizumab pegol [127, 128] | + | + | + | + | Unknowna |
Anti-IL-12/23 antibody | |||||
Ustekinumab [124, 202] | + | + | + | + | Unknown |
IL interleukin, TNF tumour necrosis factor
aThe efficacy of anti-TNF-α antibodies in axial involvement has not been directly evaluated in PsA trials. Treatment responses reported in ankylosing spondylitis are used to indicate efficacy in this condition [129]